Compare BLUE Stock to Peers
|Symbol||Last Price||Market Cap||% Δ 1 Yr||% Δ 5 Yr|
News & Analysis: Bluebird Bio
It's going to be an interesting next 12 months for the biotech.
The expected upcoming catalysts might not be all that the company needs.
The unexpected departure of its CFO and an ominous note of caution rattled investors.
The biotech's financial position has some investors worried.
Today's losers are selling for peanuts, and they just might become tomorrow's winners.
These companies have taken a beating, and there's no relief on the horizon.
These two companies are down, but they aren't yet out.
The biotech's latest corporate update wasn't well received by investors this week.
The FDA placed a partial clinical hold on Bluebird's clinical studies of lovo-cel.